How Gilead Profited by Slow-Walking a Promising H.I.V. Therapy
In 2004, Gilead Sciences decided to stop pursuing a new H.I.V. drug. The public explanation was that it wasn’t sufficiently different from an existing treatment to warrant further development. In private, though, something else was at play. Gilead had devised a plan to delay the new drug’s release to maximize profits, even though executives had…